GH Research (GHRS) Other Non Operating Income (2021 - 2025)
GH Research (GHRS) recorded quarterly Other Non Operating Income of -$140000.0 in Q4 2025, down 105.5% quarter-over-quarter from $2.5 million in Q3 2025, and up 93.6% on a YoY basis from -$72314.6 in Q4 2024.
GH Research (GHRS) Other Non Operating Income (2021 - 2025) Analysis & Trends
GH Research's Other Non Operating Income history runs 5 years deep, the most recent figure standing at -$140000.0 for Q4 2025.
- In Q4 2025, Other Non Operating Income rose 93.6% year-over-year to -$140000.0; the TTM figure through Dec 2025 stood at $6.8 million (up 239.7% YoY), while the FY2025 annual figure was -$1.8 million, up 17.66% from the prior year.
- Other Non Operating Income was -$140000.0 for Q4 2025 at GH Research, down from $2.5 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $22.7 million in Q4 2022 to a low of -$8.3 million in Q4 2023.
- Historically, Other Non Operating Income has averaged $1.9 million across 5 years, with a median of $1.2 million in 2021.
- Biggest YoY gain for Other Non Operating Income was 1178.7% in 2022; the steepest drop was 24822.22% in 2022.
- A 5-year view of Other Non Operating Income shows it stood at $2.5 million in 2021, then surged by 797.71% to $22.7 million in 2022, then slumped by 136.76% to -$8.3 million in 2023, then surged by 73.8% to -$2.2 million in 2024, then surged by 93.6% to -$140000.0 in 2025.
- The last three Other Non Operating Income figures came in at -$140000.0 (Q4 2025), $2.5 million (Q3 2025), and $2.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | GH Research | 9.73 Bn | 9.63 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -140,000.00 |
| Sep 30, 2025 | 2.55 Mn |
| Jun 30, 2025 | 2.50 Mn |
| Mar 31, 2025 | 1.92 Mn |
| Dec 31, 2024 | -2.19 Mn |
| Sep 30, 2024 | -1.85 Mn |
| Jun 30, 2024 | 466,000.00 |
| Mar 31, 2024 | -1.32 Mn |
| Dec 31, 2023 | -8.35 Mn |
| Sep 30, 2023 | 4.07 Mn |
| Jun 30, 2023 | 2.20 Mn |
| Mar 31, 2023 | -1.64 Mn |
| Dec 31, 2022 | 22.71 Mn |
| Sep 30, 2022 | 6.19 Mn |
| Jun 30, 2022 | 7.08 Mn |
| Mar 31, 2022 | -2.24 Mn |
| Dec 31, 2021 | 2.53 Mn |
| Sep 30, 2021 | 2.83 Mn |
| Jun 30, 2021 | 554,000.00 |
| Mar 31, 2021 | -9,000.00 |